Ramucirumab 100mg (Ramucirumab)
Description of Cyramza 100mg (Ramucirumab 100mg)
Cyramza 100mg (Ramucirumab 100mg) belongs to Intravenous human monoclonal antibody which prohibits VEGFR2and it increased the haemorrhage risk which may be serious and sometimes fatal. Stop if severe bleeding occurs.
Cyramza 100mg (Ramucirumab 100mg) is a prescription drugs which is used under supervision of doctor
INDICATIONS of Cyramza 100mg (Ramucirumab 100mg)
Cyramza 100mg (Ramucirumab 100mg) injection indicated for;
• As a single agent, or in concomitant use with paclitaxel for the treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
• In concomitant use with docetaxel for the treatment for metastatic non-small cell lung cancer
• In concomitant use with FOLFIRI for the treatment of patients with metastatic colorectal cancer
MECHANISM OF ACTION of Cyramza 100mg (Ramucirumab 100mg)
Ramucirumab belongs to vascular endothelial growth factor receptor 2 antagonist which efficiently binds VEGF Receptor 2 and stops binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D.
As a result, ramucirumab prohibits ligand-stimulated activation of VEGF Receptor 2, thereby prohibiting ligand-induced multiplication, and migration of human endothelial cells.
Ramucirumab prevented angiogenesis in an in vivo animal model.
Half-life of ramucirumab 14 days
SIDE EFFECTS of Cyramza 100mg (Ramucirumab 100mg)
• Peripheral edema
• Infusion-related reactions
• Hypertension grade 3-4
• Hypoalbuminemia .
PRECAUTIONS of Cyramza 100mg (Ramucirumab 100mg)
Increased the risk of haemorrhage and gastrointestinal haemorrhage, containing severe and sometimes fatal haemorrhagic events enduringly discontinue patients who experience severe bleeding
The drug may have high the risk of gastrointestinal perforation, a probably fatal event
Completely stop in patients who experience a gastrointestinal perforation
Impaired wound healing can appear with antibodies prohibiting the VEGF pathway
Avoid in patients with impaired wound healing
Hold up drug prior to surgery and discontinue if a patient occurs wound healing complications
DRUG INTERACTION of Cyramza 100mg (Ramucirumab 100mg)
Cyramza 100mg (Ramucirumab 100mg) has No clinically meaningful difference in the exposure of either ramucirumab or its combination drugs in the approved combinations, contains paclitaxel, docetaxel, and irinotecan were observed in patients with solid tumor
PREGNANCY of Cyramza 100mg (Ramucirumab 100mg)
Pregnancy, lactation, pediatric:
Based on mechanism ramucirumab will cause fetal harm. Cyramza 100mg (Ramucirumab 100mg) has no available data while use in pregnant women to inform any drug–associated risks.
LACTATION of Cyramza 100mg (Ramucirumab 100mg)
Excretion into human milk is unknown. Avoid the Cyramza 100mg (Ramucirumab 100mg) during treatment.
DOSAGE of Cyramza 100mg (Ramucirumab 100mg)
Non-Small Cell Lung Cancer :
The usual dose is 10 mg/kg IV infused over ~1 hr prior to docetaxel (75 mg/m²) IV infusion on Day 1 of a 21-day cycle. Continue until disease progression or unacceptable toxicity
As a monotherapy agent or in co administration with paclitaxel is used.
Usual dose for Single agent or in combination with paclitaxel is 8 mg/kg IV q2wk; infuse over 1 hr
Usual dose for Paclitaxel (if given in combination) is 80 mg/m² once weekly for 3 weeks of every 28-day cycle.
When given in concomitant, administer ramucirumab prior to administration of paclitaxel. Follow until disease progression or unacceptable toxicity
In combination with FOLFIRI for the treatment
Usual dose is 8 mg/kg IV q2wk; administer by IV infusion over 60 minutes prior to FOLFIRI administration. Follow until disease progression or unacceptable toxicity
STORAGE of Cyramza 100mg (Ramucirumab 100mg)
Store the vial at 2℃ to 8℃ Discard product if it contains particulate matter, is cloudy, or discoloured Dispose unused portion. Do not store for later use.
Take the dose immediately before next dose duration, Next dose time reaches then left off the missed dose and continue regular schedule. Avoid taking double dose at same time. Please consult the doctor for further information.
No reviews found